Papanek Julie Grant is Director at Day One Biopharmaceuticals, Inc. (DAWN). They have made 5 open-market trades across 1 company since 2021, most recently 2022-09-02.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $208K since 2021, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| DAWN | 439,358 | $9.5M |
Shares reported on the most recent Form 4, priced at the 2022-09-15 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DAWN | SELL | 2022-09-02 | 2022-09-15 | $23.82 | $119K | -13.1% | -11.0% | -2.2% |
| DAWN | SELL | 2022-09-01 | 2022-09-06 | $23.24 | $220K | -8.1% | -12.5% | -8.5% |
| DAWN | SELL | 2022-08-04 | 2022-08-08 | $20.00 | $200K | -0.2% | +1.5% | -19.0% |
| DAWN | SELL | 2022-07-18 | 2022-07-20 | $20.00 | $52K | -15.3% | +23.3% | -0.3% |
| DAWN | SELL · 10b5-1 | 2022-07-08 | 2022-07-12 | $20.00 | $25K | +3.4% | +40.5% | +12.5% |
| DAWN | SELL · 10b5-1 | 2022-07-01 | 2022-07-12 | $20.00 | $36K | +3.4% | +40.5% | +12.5% |
| DAWN | BUY | 2021-06-01 | 2021-06-02 | $16.00 | $208K | -7.5% | +3.1% | +25.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.